1.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
2.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and over Sponsor: Other Protocol IDs: I07028, N° EudraCT : 2008-001195-7, NCT00812864
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2009-03, NCT00868569
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2009-04, NCT00874406
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: Oxali04882, NCT01023633
|
|
6.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 20110101, NCT01307878
|
|
7.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DERMATUX, NCT01315990
|
|
8.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PROFUSE-2011, NCT01468623
|
|
9.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-008104, NCT01471756
|
|
10.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEMCAD-1006, NCT01493713
|
|
11.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2012-03, NCT01564810
|
|
12.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25753, NCT01588990
|
|
13.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: SG 343/12, NCT01641458
|
|
14.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
15.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: AMT/P2GI/001 Part III, LC001Auron2005, NCT00405561
|
|
16.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 08-PIR-03, NCT00856375
|
|
17.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCL-08/0079, CRUK-UCL-ISAAC01, UCL-ISAAC, ISRCTN10963271, EU-21008, CRUK-C32436/A10431, EUDRACT-2008-005911-16, MREC-09/H1102/60, NCRI-UCL-08/0079, NCT01086618
|
|
18.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: JBZ-EnRoute+, EnRoute+, EUDRACT-2010-018612-32, EU-21016, NCT01097265
|
|
19.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UW09-341, NCT01101672
|
|
20.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: CR01/18/10, NCT01189903
|
|
21.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: CDK-122099, StateKeyLab, NCT01196260
|
|
22.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: JH-RC-001, NCT01386242
|
|
23.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-1207, 2012-002317-18, NCT01646554
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: FFCD 2000 – 05, CET 815, NCT00126256
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRE-2002.445-T, NCT00164879
|